Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: A multicentre observational study

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 666-672

  Esposito, M ^a   Gisondi, P ^b   Cassano, N ^c   Ferrucci, G ^d   Del Giglio, M ^b   Loconsole, F ^c   Giunta, A ^a   Vena, G A ^c   Chimenti, S ^a   Girolomoni, G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Informa Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL PRACTICE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DERMATOLOGIST; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LONG TERM SURVIVAL; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENINGIOMA; MONOTHERAPY; MOTOR DYSFUNCTION; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE CANCER; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RHEUMATOLOGY; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOSIS; THYROID NODULE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84883322009     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12422     Document Type: Article

References (20)

1. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
2. Glintborg B, Østergaard M, Dreyer L, et al,. Treatment response, drug survival, and predictors in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
3. Saad AA, Ashcroft DM, Watson KD, et al,. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
4. Brunasso AM, Puntoni M, Massone C,. Drug survival rate of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 2012; 166: 447-9.
5. Noiles K, Vender R,. Biologic survival. J Drugs Dermatol 2009; 8: 329-33.
6. Chan SA, Hussain F, Lawson LG, Ormerod AD,. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat 2013; 24: 64-9.
7. Saougou I, Markatseli TE, Papagoras C, et al,. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40: 398-406.
8. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
9. Taylor W, Gladman D, Helliwell P, et al,. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
10. Lucka TC, Pathirana D, Sammain A, et al,. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-44.
11. Strohal R, Chimenti S, Vena GA, Girolomoni G,. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat 2013; 24: 199-208.
12. Girolomoni G, Altomare G, Ayala F, et al,. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012; 34: 548-60.
13. Gisondi P, Tessari G, Di Mercurio M, et al,. Retention rate of systemic drugs in patients with chronic plaque psoriasis. Clin Dermatol 2013; 1: 8-14.
14. Gisondi P, Cazzaniga S, Chimenti S, et al,. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare registry. J Eur Acad Dermatol Venereol 2012; 147: 483-9.
15. Elliott RA, Barber N, Horne R,. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508-15.
16. Lamb CA, Fried RG, Feldman SR,. Giving patients 'perceived control' over psoriasis: advice for optimizing the physician-patient relationship. J Dermatolog Treat 2004; 15: 182-4.
17. Mehren CR, Gniadecki R,. Dose-creep of infliximab during psoriasis treatment: an observational study. Acta Derm Venereol 2012; 92: 355-7.
18. Warren RB, Brown BC, Lavery D, et al,. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-9.
19. Driessen RJB, Boezeman JB, van de Kerkhof PCM, de Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-5.
20. Vena GA, Cassano N, Piaserico S, et al,. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacol Immunotoxicol 2012; 34: 901-6.